Sensitization to doxorubicin resistance in breast cancer cell lines by tamoxifen and megestrol acetate

This publication has 20 references indexed in Scilit:

• A randomized comparison of single-agent doxorubicin and epirubicin as first-line cytotoxic therapy in advanced breast cancer.
  Journal of Clinical Oncology, 1991
• Toremifene: pharmacologic and pharmacokinetic basis of reversing multidrug resistance.
  Journal of Clinical Oncology, 1989
• Multidrug Resistance1
  JNCI Journal of the National Cancer Institute, 1988
• Cyclosporin A corrects daunorubicin resistance in Ehrlich ascites carcinoma
  British Journal of Cancer, 1986
• The eastern cooperative oncology group experience with cyclophosphamide, adriamycin, and 5-fluorouracil (CAF) in patients with metastatic breast cancer
  Cancer, 1985
• Comparison of induction chemotherapies for metastatic breast cancer. An eastern cooperative oncology group trial
  Cancer, 1982
• Comparison of four-combination chemotherapy programs in metastatic breast cancer. Comparison of multiple drug therapy with cytoxan, 5-fu and prednisone versus cytoxan and adriamycin, versus cytoxan, 5-Fu and adriamycin, versus cytoxan, 5-Fu and prednisone alternating with cytoxan and adriamycin
  Cancer, 1982
• Chemotherapy of advanced breast cancer: A randomized trial of vincristine, adriamycin, and cyclophosphamide (VAC) versus cyclophosphamide, methotrexate, 5-fluorouracil, and prednisone (CMFP)
  Cancer, 1981
• Adriamycin versus methotrexate in five-drug combination chemotherapy for advanced breast cancer. A randomized trial
  Cancer, 1978
• Combination chemotherapy and adriamycin in patients with advanced breast cancer.A Southwest Oncology Group study
  Cancer, 1976